Full Press Release Details
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster presentations atIMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists taking place in Boston, Massachusetts, April 15-19, 2026.
“We are excited to share these preclinical findings that support the differentiated profile of EQ504 as a potent AhR modulator, with the potential to influence both immune cell responses and barrier restoration,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “Together, these attributes are particularly important in diseases such as ulcerative colitis, where both reducing inflammation and improving mucosal healing are critical to achieving meaningful outcomes for patients.”
Details of the presentations:Abstract title:EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine ReleaseSession:Immune Response Regulation: Cellular Mechanisms IPresentation Type:Poster Abstract PresentationPresentation Location & Time:Exhibit Hall, Thursday April 16, 2026Session Time:9:00 AM - 4:30 PM EDTPoster Board Number:242Speaker at Poster:2:30 PM - 3:30 PM EDTAbstract title:EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR AgonistsSession:Immunology of Barrier SurfacesPresentation Type:Poster Abstract PresentationPresentation Location & Time:Exhibit Hall, Saturday April 18, 2026Session Time:9:00 AM - 4:30 PM EDTPoster Board Number:517Speaker at Poster:11:30 AM - 12:30 PM EDT
Following each presentation, the posters will be available on thePresentationspage, located under the Technology section onequilliumbio.com.
About EQ504EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
For more information, visitwww.equilliumbio.com.